Novartis has agreed to acquire Excellergy, a biotechnology company developing a novel class of allergy therapeutics, in a transaction with a total potential value of up to $2 billion in upfront and milestone payments.   Excellergy’s Exl-111 is a trifunctional effector cell response inhibitor (ECRI) designed to disarm allergic effector cells at the source of activation […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!